A highly functional synthetic phage display library containing over 40 billion human antibody clones

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Weber, Marcel ^a,b   Bujak, Emil ^a,b   Putelli, Alessia ^a,b   Villa, Alessandra ^b   Matasci, Mattia ^b   Gualandi, Laura ^b   Hemmerle, Teresa ^b   Wulhfard, Sarah ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b PHILOCHEM AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARRIER PROTEIN; COLLAGEN TYPE 1; FIBRONECTIN; FOLLISTATIN; FOLLISTATIN LIKE PROTEIN 1; GLUTATHIONE TRANSFERASE; INTERSTITIAL COLLAGENASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G5; MYCOLACTONE; PENTRAXIN; PENTRAXIN RELATED PROTEIN 3; PROTEASOME; PROTEASOME 26S; PROTEIN A; SERINE PROTEINASE INHIBITOR; STROMELYSIN; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE; UBIQUILIN 1; UNCLASSIFIED DRUG; PEPTIDE LIBRARY;

ANTIBODY ISOLATION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CHRONIC INFLAMMATION; CONTROLLED STUDY; GENE LIBRARY; HUMAN; MOLECULAR CLONING; PHAGE DISPLAY; PROTEIN EXPRESSION; ANIMAL; ANTIBODY SPECIFICITY; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; IMMUNOLOGY; MOUSE; PEPTIDE LIBRARY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CLONING, MOLECULAR; HUMANS; MICE; MODELS, MOLECULAR; PEPTIDE LIBRARY; PROTEIN STRUCTURE, TERTIARY; TENASCIN;

EID: 84903288764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100000     Document Type: Article

References (57)

1. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341: 1192-1198.
2. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12: 615-622.
3. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315-1317.
4. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR (1994) Making antibodies by phage display technology. Annu Rev Immunol 12: 433-455.
5. Lerner RA, Kang AS, Bain JD, Burton DR, Barbas CF, 3rd (1992) Antibodies without immunization. Science 258: 1313-1314. (Pubitemid 23007779)
6. Clackson T, Hoogenboom HR, Griffiths AD, Winter G (1991) Making antibody fragments using phage display libraries. Nature 352: 624-628. (Pubitemid 21912394)
7. Merz DC, Dunn RJ, Drapeau P (1995) Generating a phage display antibody library against an identified neuron. J Neurosci Methods 62: 213-219. (Pubitemid 3014047)
8. Marks JD, Griffiths AD, Malmqvist M, Clackson TP, Bye JM, et al. (1992) By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y) 10: 779-783.
9. Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12: 3200-3208. (Pubitemid 43837370)
10. Hoogenboom HR, Winter G (1992) By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J Mol Biol 227: 381-388.
11. Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotny J, et al. (1988) Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci U S A 85: 5879-5883.
12. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, et al. (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122: 2405-2413. (Pubitemid 351590471)
13. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, et al. (1998) Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 273: 21769-21776. (Pubitemid 28405353)
14. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, et al. (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33: 1718-1722.
15. Schwager K, Villa A, Rosli C, Neri D, Rosli-Khabas M, et al. (2011) A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol 3: 25.
16. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, et al. (2009) Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 11: R142.
17. Schliemann C, Neri D (2007) Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 1776: 175-192. (Pubitemid 350061071)
18. Schliemann C, Neri D (2010) Antibody-based vascular tumor targeting. Recent Results Cancer Res 180: 201-216.
19. Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, et al. (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5: 201ra118.
20. Silacci M, Brack S, Schirru G, Marlind J, Ettorre A, et al. (2005) Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics 5: 2340-2350. (Pubitemid 40835403)
21. Villa A, Lovato V, Bujak E, Wulhfard S, Pasche N, et al. (2011) A novel synthetic naive human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin. MAbs 3: 264-272.
22. Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K (2011) High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 16: 3675-3700.
23. Ravenni N, Weber M, Neri D (2013) A human monoclonal antibody specific to placental alkaline phosphatase, a marker of ovarian cancer. MAbs 6.
24. Tomlinson IM, Walter G, Marks JD, Llewelyn MB, Winter G (1992) The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J Mol Biol 227: 776-798.
25. Tomlinson IM, Walter G, Jones PT, Dear PH, Sonnhammer EL, et al. (1996) The imprint of somatic hypermutation on the repertoire of human germline V genes. J Mol Biol 256: 813-817. (Pubitemid 26108820)
26. Chothia C, Lesk AM, Gherardi E, Tomlinson IM, Walter G, et al. (1992) Structural repertoire of the human VH segments. J Mol Biol 227: 799-817.
27. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, et al. (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19: 4133-4137. (Pubitemid 21912784)
28. Balza E, Siri A, Ponassi M, Caocci F, Linnala A, et al. (1993) Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin. FEBS Lett 332: 39-43. (Pubitemid 23295894)
29. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, et al. (1999) Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 154: 1345-1352. (Pubitemid 29226429)
30. Silacci M, Brack SS, Spath N, Buck A, Hillinger S, et al. (2006) Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel 19: 471-478. (Pubitemid 44408907)
31. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, et al. (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102: 75-85.
32. List T, Neri D (2012) Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs 4: 775-783.
33. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, et al. (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 13: 3245-3260. (Pubitemid 24226939)
34. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136. (Pubitemid 41486394)
35. Midwood KS, Hussenet T, Langlois B, Orend G (2011) Advances in tenascin-C biology. Cell Mol Life Sci 68: 3175-3199.
36. Zuberbuhler K, Palumbo A, Bacci C, Giovannoni L, Sommavilla R, et al. (2009) A general method for the selection of high-level scFv and IgG antibody expression by stably transfected mammalian cells. Protein Eng Des Sel 22: 169-174.
37. Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, et al. (2010) Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 103: 827-836.
38. Schwager K, Bootz F, Imesch P, Kaspar M, Trachsel E, et al. (2011) The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model. Hum Reprod 26: 2344-2352.
39. Marks JD, Bradbury A (2004) Selection of human antibodies from phage display libraries. Methods Mol Biol 248: 161-176.
40. Chothia C, Lesk AM (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196: 901-917. (Pubitemid 17127946)
41. Al-Lazikani B, Lesk AM, Chothia C (1997) Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273: 927-948. (Pubitemid 27493729)
42. Morea V, Tramontano A, Rustici M, Chothia C, Lesk AM (1997) Antibody structure, prediction and redesign. Biophys Chem 68: 9-16. (Pubitemid 28064649)
43. Tomlinson IM, Cox JP, Gherardi E, Lesk AM, Chothia C (1995) The structural repertoire of the human V kappa domain. EMBO J 14: 4628-4638.
44. Ma X, Barthelemy PA, Rouge L, Wiesmann C, Sidhu SS (2013) Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor. J Mol Biol 425: 2247-2259.
45. Rothlisberger D, Honegger A, Pluckthun A (2005) Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 347: 773-789. (Pubitemid 40357919)
46. Hoogenboom HR, Marks JD, Griffiths AD, Winter G (1992) Building antibodies from their genes. Immunol Rev 130: 41-68. (Pubitemid 23014841)
47. Rothe C, Urlinger S, Lohning C, Prassler J, Stark Y, et al. (2008) The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies. J Mol Biol 376: 1182-1200.
48. Pedretti M, Soltermann A, Arni S, Weder W, Neri D, et al. (2009) Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 64: 28-33.
49. Pedretti M, Rancic Z, Soltermann A, Herzog BA, Schliemann C, et al. (2010) Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis 208: 382-389.
50. Senter PD (2009) Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13: 235-244.
51. Casi G, Neri D (2012) Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 161: 422-428.
52. Bernardes GJ, Casi G, Trussel S, Hartmann I, Schwager K, et al. (2012) A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 51: 941-944.
53. Chari RV (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41: 98-107.
54. Steiner M, Neri D (2011) Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 17: 6406-6416.
55. Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17: 583-590.
56. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, et al. (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14: 6515-6524.
57. Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, et al. (2014) Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 41: 867-877.